1. Home
  2. SINT vs KPRX Comparison

SINT vs KPRX Comparison

Compare SINT & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SiNtx Technologies Inc.

SINT

SiNtx Technologies Inc.

HOLD

Current Price

$1.50

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.54

Market Cap

11.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SINT
KPRX
Founded
1996
1998
Country
United States
United States
Employees
N/A
13
Industry
Medical/Dental Instruments
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.1M
11.7M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
SINT
KPRX
Price
$1.50
$2.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$11.00
$10.00
AVG Volume (30 Days)
23.3K
16.4K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
59.45
N/A
EPS
N/A
N/A
Revenue
$1,018,000.00
N/A
Revenue This Year
$30.26
N/A
Revenue Next Year
$413.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.47
$1.76
52 Week High
$6.78
$3.06

Technical Indicators

Market Signals
Indicator
SINT
KPRX
Relative Strength Index (RSI) 27.68 48.01
Support Level N/A $2.44
Resistance Level $2.98 $2.61
Average True Range (ATR) 0.10 0.09
MACD -0.00 -0.00
Stochastic Oscillator 4.56 71.43

Price Performance

Historical Comparison
SINT
KPRX

About SINT SiNtx Technologies Inc.

SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: